



SIXTEENTH ANNUAL **ELLIOT'S LEGACY** KITES FOR A CURE

A SKY FULL OF
KITES & HEARTS
FILLED WITH **HOPE**

Sunday, Aug 20, 2023 | 10 AM

WELCOME

Thank you for being part of Elliot's Legacy Kites for a Cure! We're happy to be back for kite flying and family fun.

The Fifteenth Annual Elliot's Legacy event took place on Sunday, July 10, 2022 and raised over \$540,000 for lung cancer research in what was one of the most anticipated events of the summer.

We look forward to another great day making an impact as we gather by the ocean with our friends and families!



Hy, Raymond, and Richard Chalmé

ABOUT ELLIOT CHALMÉ – AND WHY WE FLY KITES IN HIS MEMORY

Elliot's Legacy was founded in memory of Elliot Chalmé A'H by family and friends. Elliot passed away from lung cancer in 2006 at the age of 56. His legacy continues to live on through his wife, sons, grandchildren and all who knew him.

Elliot had a natural ability to touch people's lives with great one liners and a charismatic smile. A true friend to the young and old, his love for people impacted all who knew him. Elliot treated every person he encountered as a beloved friend.

"Dad was a family man and knowing that this event continues to bring together so many people would certainly make him smile," said the Chalmé family. "We are so grateful to

the hundreds of sponsors and attendees who help us to raise awareness about lung cancer and bring much needed attention to supporting critical research."

"Smile. People can never be mean to a smile. It will open many doors."

– Elliot R. Chalmé



Founded in 2005, LCRF funds novel

lung cancer research

that might otherwise go unfunded.




To date, LCRF has funded

409

research grants, totaling over

\$43 million.

SINCE INCEPTION, ELLIOT'S LEGACY HAS RAISED MORE THAN **\$7 MILLION** FOR THE LUNG CANCER RESEARCH FOUNDATION. LCRF'S GRANTEES HAVE GONE ON TO RECEIVE MORE THAN **\$70 MILLION** IN FOLLOW-UP FUNDING.

THE FACTS ABOUT LUNG CANCER

Lung cancer is
**the number one
cancer killer**
worldwide

In the US, the five-year
survival rate for lung cancer is
23 percent

An estimated
348 Americans
die from lung cancer
every day

In the US, **more people**
die of lung cancer than
breast, pancreatic, and
prostate cancer combined

THE IMPACT OF RESEARCH FUNDING ON LUNG CANCER

Thanks to advances in research and development of new treatments, more personalized treatments are now available to lung cancer patients. Through trials such as those conducted by the Lung Cancer Mutation Consortium, LCRF is helping to bring the next generation of biomarker testing and targeted therapies to as many patients as possible.

Learn more about LCRF's Grant Program at [LCRF.org/research](https://www.lcrf.org/research)

“When I started my career as an independent investigator at Dana-Farber, I received one of my very first grant awards from the Lung Cancer Research Foundation. My career was launched because of this grant and donors' generosity.”

Kwok-Kin Wong, MD, PhD

*New York University Langone Medical Center
LCRF Grant Recipient*

“I am very grateful to receive support from LCRF... This funding enabled us to understand how a tumor spreads throughout the body to ultimately guide the development of better treatments.”


Christopher Maher, PhD

*McDonnell Genome Institute
LCRF Grant Recipient*

HISTORY OF LUNG CANCER TREATMENT ADVANCES

Lung cancer treatments available in the past were few and far between. Fortunately, since the early 2000s, we observed a steep increase in the number and variety of treatments available for lung cancer.

See below left for a list of treatment drugs approved since the 1940s.



DRUG APPROVALS BY DECADE 1940-PRESENT

- | | | |
|--|--|--|
| <p>1940s</p> <ul style="list-style-type: none"> • Mechlorethamine Hydrochloride <p>1970s</p> <ul style="list-style-type: none"> • Methotrexate • Doxorubicin Hydrochloride <p>1980s</p> <ul style="list-style-type: none"> • Cisplatin <p>1990s</p> <ul style="list-style-type: none"> • Etoposide / Etoposide Phosphate • Gemcitabine Hydrochloride • Vinorelbine Tartrate <p>2000s</p> <ul style="list-style-type: none"> • Bevacizumab • Carboplatin • Docetaxel | <ul style="list-style-type: none"> • Erlotinib Hydrochloride • Everolimus • Gefitinib • nab-Paclitaxel • Pemetrexed Disodium • Topotecan Hydrochloride <p>2010s</p> <ul style="list-style-type: none"> • Afatinib Dimaleate / Afatinib • Alectinib • Atezolizumab • Brigatinib • Ceritinib • Crizotinib • Dabrafenib Mesylate • Dacomitinib • Durvalumab • Entrectinib • Larotrectinib • Lorlatinib | <ul style="list-style-type: none"> • Necitumumab • Nivolumab • Osimertinib Mesylate • Pembrolizumab • Ramucirumab • Trametinib Dimethyl Sulfoxide <p>2020s</p> <ul style="list-style-type: none"> • Amivantamab-vmjw • Capmatinib Hydrochloride • Cemiplimab-rwlc • Ipilimumab • Lurbinectedin • Mobocertinib Succinate • Pralsetinib • Selpercatinib • Sotorasib • Tepotinib Hydrochloride |
|--|--|--|

LCRF funding supports advances in lung cancer research such as:

Basic and clinical science driving development of targeted therapies.



Identification of biomarkers for treatment resistance.



Discovery of new immunotherapy treatments that prolong lung cancer remission.



Quadrupling advanced stage non-small cell lung cancer 5-year survival rate in under 10 years.



Support for world-wide research into all areas of unmet need in lung cancer.





2022

ELLIOT'S LEGACY

